This pattern was not significantly different at 2 h and 24 h postcontrast (p=0.82). On ferumoxytol-enhanced T2-FSE images, benign lymph nodes showed a hypointense hilum and hyperintense parenchyma, while malignant lymph nodes showed no discernible hilum. Results: We examined a total of 613 lymph nodes, of which 464 (75.7%) were benign and 149 (24.3%) were malignant. Follow-up imaging for at least 6 months served as the standard of reference. The accuracy of different criteria was assessed with a receiver operating characteristics (ROC) curve. In addition, ADCmean-values, SUV-ratio (SUV max lesion/SUV mean liver) and R2*-relaxation rate of benign and malignant lymph nodes were compared with a Mann-Whitney-U test. The morphology of benign and malignant lymph nodes on ferumoxytol-enhanced T2-FSE sequences at 2 and 24 h were compared using a linear regression analysis. Forty-two children (7-18 years, 29 male, 13 female) received a 18F-FDG PET/MRI at 2 (n=20) or 24 hours (h) (n=22) after intravenous injection of ferumoxytol (dose 5 mg Fe/kg). Ferumoxytol is an FDA-approved iron supplement for the treatment of anemia and has been used “off-label” as an MRI contrast agent in this study. Methods: We conducted a prospective clinical trial from May 2015 to December 2018 to investigate the value of ferumoxytol nanoparticles for staging of children with cancer with 18F-FDG PET/MRI. The purpose of our study was to evaluate if the iron supplement ferumoxytol improves the differentiation of benign and malignant lymph nodes in pediatric cancer patients on 18F-FDG PET/MRI. Therefore, previously described biodistributions of iron oxide nanoparticles in benign and malignant lymph nodes of adult patients may not apply to children. Most notably, normal lymph nodes in children contain less macrophages. The composition of lymph nodes in pediatric patients is different from that in adults. Select the file that you have just downloaded and select import option Reference Manager (RIS). Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Muehe AM, Siedek F, Theruvath AJ, Seekins J, Spunt SL, Pribnow A, Hazard FK, Liang T, Daldrup-Link H. H.E.Daldrup-Linkedu Department of Radiology, Lucile Packard Children's Hospital, Stanford School of Medicine, 725 Welch Rd, Stanford, CA 94305-5654, Ph (lab): (650) 723-1127, fax: (650) 725-8957 More Department of Pathology, Division of Hematology and Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA Department of Pediatrics, Division of Hematology and Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USAĥ. Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, GermanyĤ. Institute of Diagnostic and Interventional Radiology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germanyģ. Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, USAĢ. Spunt 4, Allison Pribnow 4, Florette Kimberly Hazard 5, Tie Liang 1, Heike Daldrup-Link 1,4ġ. Research Paper Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRIĪnne Monika Muehe 1*, Florian Siedek 1,2*, Ashok Joseph Theruvath 1,3, Jayne Seekins 1, Sheri L.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |